tbuckley/cabot-search huggingface dataset:
Abstract 2531: The selective CCR9 antagonist CCX8037 inhibits CCL25-CCR9-STAT3 mediated proliferation of pancreatic cancer cells
Authors: Jianming Lu, Xiaoming Shen, Brian Mailey, Andrew M. Lowy, Joseph Kim
Journal: Cancer Research (2010)

Abstract Introduction: We previously reported the expression of CCR9 in pancreatic intraepithelial neoplasia (PanIN) and invasive pancreatic cancer tissues. Here, our objective was to investigate signaling downstream of CCR9 and to determine the anti-proliferative effects of the candidate therapeutic CCR9 antagonist CCX8037. Methods: PanIN and corresponding invasive pancreatic cancer (5143PDA) and liver metastasis (5143LM) cell lines were derived from Pdx-1-Cre;LSL-K-rasG12D and Pdx-1-Cre;LSL-K-rasG12D/p53R172H mice. In culture, murine and human pancreatic cancer cells (PANC-1) were exposed to CCL25, the specific CCR9 ligand. The phosphorylation of STAT3, an established regulator of pancreatic cancer proliferation, was measured by Western blot assay and proliferation assays were performed with the small molecule CCX8037 and the JAK/STAT inhibitor AG490. Results: First, we verified that exposure to CCL25 enhanced cell proliferation (20%-40%) in both murine and human pancreatic cancer cells. To investigate CCL25/CCR9 signaling, we exposed cells to CCL25 and observed increased phosphorylation of STAT3 in the cells. Blockade of STAT3 signaling with AG490 abrogated CCL25/CCR9-mediated proliferation in both murine and human pancreatic cancer cells. Pre-treatment of PanIN and pancreatic cancer cells with CCX8037 blocked CCL25-mediated phosphorylation of STAT3 and inhibited CCL25-mediated cell proliferation. Conclusion: Our study demonstrates for the first time that the CCL25/CCR9 axis activates downstream STAT3 signaling to mediate proliferation in murine and human PanIN and pancreatic cancer cells. Additionally, our data shows that the candidate therapeutic agent CCX8037 effectively blocks CCL25/CCR9-mediated proliferation in pancreatic cancer and warrants investigation in vivo. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2531.
Germline fumarate hydratase mutations and evidence for a founder mutation underlying multiple cutaneous and uterine leiomyomata
Authors: Gary S. Chuang, Amalia Martinez-Mir, Adam Geyer, Danielle E. Engler, Benjamin Glaser, Peter B. Cserhalmi-Friedman, Derek Gordon, Liran Horev, Barbara Lukash, Eric Herman, Manuel Prieto Cid, Sarah Brenner, Marina Landau, Eli Sprecher, Maria Pilar Garcia Muret, Angela M. Christiano, Abraham Zlotogorski
Journal: Journal of the American Academy of Dermatology (2005)
Immunosuppressive factors from lymphoid cells of nonresponder mice primed with L-glutamic acid60-L-alanine30-L-tyrosine10. IV. Lack of strain restrictions among allogeneic, nonresponder donors and recipients.
Authors: J A Kapp
Journal: The Journal of Experimental Medicine (1978)

The synthetic terpolymer of L-glutamic acid60-L-alanine30-L-tyrosine10 (GAT) fails to stimulate development of GAT-specific antibody responses in nonresponder mice but stimulates development of GAT-specific suppressor T cells that inhibit the development of normal anti-GAT plaque-forming cell responses to GAT complexed to methylated bovine serum albumin (MBSA). Extracts from lymphoid cells of GAT-primed but not control, nonresponder (DBA/1) mice contain a T-cell factor (GAT-TsF) that also specifically suppresses responses to GAT-MBSA by normal syngeneic spleen cells. The experiments reported in this communication demonstrate that: (a) extracts from all GAT-primed nonresponder mice tested contain GAT-TsF; (b) non-H-2 genes do not restrict the production of GAT-TsF; (c) all nonresponder strains of mice regardless of their non-H-2 genes are suppressed by GAT-TsF from all other strains bearing the nonresponder H-2p,q,s haplotypes; (d) suppression of GAT-MBSA responses by both syngeneic and allogeneic nonresponder spleen cells is mediated by a molecule encoded by the H-2 gene complex; and (e) both syngeneic and allogeneic nonresponder mice are suppressed by purified GAT-TsF that lacks immunoreactive GAT.
Maybe More Is Better
Authors: Tate Thigpen
Journal: Journal of Clinical Oncology (2003)

Article Tools EDITORIALS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.93.115 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12829661 Maybe More Is Better Tate ThigpenxTate ThigpenSearch for articles by this author Show More Division of Oncology, University of Mississippi Medical Center, Jackson, MS https://doi.org/10.1200/JCO.2003.93.115 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology
Inhibition of angiogenesis by IL-32: Possible role in asthma
Authors: Norbert Meyer, Janine Christoph, Heidi Makrinioti, Philippe Indermitte, Claudio Rhyner, Michael Soyka, Thomas Eiwegger, Maciej Chalubinski, Kerstin Wanke, Hiroyuki Fujita, Paulina Wawrzyniak, Simone Bürgler, Sherrie Zhang, Mübeccel Akdis, Günter Menz, Cezmi Akdis
Journal: Journal of Allergy and Clinical Immunology (2012)
Sex and Swedish 85-Year-Olds
Authors: Ingmar Skoog
Journal: New England Journal of Medicine (1996)

To the Editor: Most studies of sexual behavior include few subjects older than 80 years of age and are conducted in highly selected samples. Our knowledge of sexual behavior in this older age group is therefore limited, but a stereotype prevails that elderly persons are asexual. My colleagues and I therefore studied sexual behavior in a representative sample of 321 85-year-olds without dementia who were living in Goteborg, Sweden. The subjects were 223 women (21 married and 202 not married) and 98 men (55 married and 43 not married). The sample has been described in detail previously.1 All subjects were . . .
Abstract 44: Tissue image analysis tool to quantify HER2 RNA and protein expression by colorimetric <i>in situ</i> hybridization and immunohistochemistry for breast cancer diagnosis.
Authors: Mirza Peljto, Joseph Krueger, Erik Hagendorn, David Young, Steve Potts, Quan Nguyen, Botoul Maqsodi, Takuro Yaoi, Gary McMaster
Journal: Cancer Research (2013)

Abstract Early cancer diagnosis and risk assessment are powerful drivers in discovery of oncology biomarkers for diagnostic tests and simultaneous improvement of already identified biomarkers. Molecular tools such as RNA Colorimetric in situ hybridization (CISH) and immunohistochemistry (IHC) combined with conventional histopathology promise to increase the sensitivity and specificity of cancer staging and overall survival prediction. Changes in oncogene and proto-oncogene expression are a hallmark of cancer. For this reason, simultaneous quantification of mRNA and protein expression using RNA CISH and IHC combined with image-analysis is of interest. One such proto-oncogene is HER2, which is encoded by ERBB2 gene located at the long arm of human chromosome 17 (17q12). Here, we combine RNA CISH and IHC with image-analysis to develop a reliable quantitative HER2 assay that enables quantification of HER2 mRNA and protein expression in the context of human breast cancer. Since HER2 is only over-expressed in a subset of human breast cancers, we initially focused our analysis by screening tissue microarrays (TMAs) using RNA CISH and IHC. TMAs containing 20 normal and 20 breast tumor tissues were tested and whole-slide imaging was used to obtain CISH and IHC signals. HER2 mRNA and protein expression were analyzed, quantified, and compared both at tissue- and individual cell-levels using proprietary image-analysis based tools. Moreover, we compared heterogeneity of RNA and protein expression and further extended our studies to several other cancer-related genes. Finally, since oncogene expression plays a role in cancer pathologies, successful quantification of oncogene in situ expression in human cancer tissues may prove to be beneficial to further understanding of cancer pathology, for drug screening and development of biomarkers and ultimately diagnostic tests. Citation Format: Mirza Peljto, Joseph Krueger, Erik Hagendorn, David Young, Steve Potts, Quan Nguyen, Botoul Maqsodi, Takuro Yaoi, Gary McMaster. Tissue image analysis tool to quantify HER2 RNA and protein expression by colorimetric in situ hybridization and immunohistochemistry for breast cancer diagnosis. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 44. doi:10.1158/1538-7445.AM2013-44
Inhibition of the anticoagulant activity of protein S by prothrombin.
Authors: C A Mitchell, S M Jane, H H Salem
Journal: Journal of Clinical Investigation (1988)

Protein S is a vitamin K-dependent protein cofactor to the anticoagulant, activated protein C (APC). This study examines the inhibition of human protein S anticoagulant activity by prothrombin. In the absence of protein S, the anticoagulant activity of APC measured in a Factor Xa recalcification time, was comparable using normal or plasma adsorbed with Al(OH)3. Protein S was an effective cofactor to APC in Al(OH)3-adsorbed plasma, but was significantly less active in normal plasma. Analysis of the difference in the two plasmas revealed that normal plasma contained an inhibitor to the anticoagulant activity of protein S that was removed by Al(OH)3 adsorption. Purification of this inhibitory activity demonstrated that it was mediated by the vitamin K-dependent protein, prothrombin. Prothrombin purified by conventional techniques caused immediate, dose-dependent inhibition of the cofactor activity of protein S in the presence of phospholipids or platelets, but had no effect on the anticoagulant activity of APC. The inhibition was demonstrable using a Factor Xa recalcification time, and studies of the rates of inactivation of purified Factor Va. Increasing concentrations of protein S overcame the inhibition by prothrombin and kinetic analysis of the interaction demonstrated that prothrombin acted as a competitive inhibitor to protein S. Immunoabsorption of prothrombin from plasma using immobilized antiprothrombin antibodies was associated with the complete removal of the protein S inhibitory activity. We conclude that the anticoagulant activity of protein S is modulated by prothrombin and that this may represent another regulatory mechanism of the natural anticoagulant system.
'Serum only' Schilling's test in patients with subtotal gastrectomy
Authors: D. L. Solanki
Journal: JAMA (1983)

To the Editor.—  Two main sources of error in the Schilling urinary excretion test for vitamin B 12 absorption are an incomplete urine collection and the presence of renal disease. The use of eight-hour plasma or serum radioactivity that coincides with peak plasma levels of the orally administered radiolabeled vitamin overcomes these drawbacks. It has been shown to correlate well with the urinary excretion method 1,2 and has replaced the urinary method in many institutions. With this method, malabsorption of vitamin B 12 reflected in a subnormal eight-hour plasma radioactivity has been reported to occur frequently in subjects with partial gastrectomy. 2 Possibly, however, a rapid transit after subtotal gastric resection may cause peak plasma levels to occur earlier than in those without a resection and thus produce a misleading low eight-hour result. To examine this question, we serially measured serum radioactivity in eight patients with subtotal gastrectomy after an
Effect of Short-Course, High-Dose Amoxicillin Therapy on Resistant Pneumococcal Carriage
Authors: Stephanie J. Schrag, Chabela Peña, Josefina Fernández, Jacqueline Sánchez, Virgen Gómez, Eddy Pérez, Jesús M. Feris, Richard E. Besser
Journal: JAMA (2001)

Context Emerging drug resistance threatens the effectiveness of existing therapies for pneumococcal infections.Modifying the dose and duration of antibiotic therapy may limit the spread of resistant pneumococci.Objective To determine whether short-course, high-dose amoxicillin therapy reduces risk of posttreatment resistant pneumococcal carriage among children with respiratory tract infections. Design and SettingRandomized trial conducted in an outpatient clinic in Santo Domingo, Dominican Republic, October 1999 through July 2000.Participants Children aged 6 to 59 months who were receiving antibiotic prescriptions for respiratory tract illness (n = 795).Interventions Children were randomly assigned to receive 1 of 2 twice-daily regimens of amoxicillin: 90 mg/kg per day for 5 days (n = 398) or 40 mg/kg per day for 10 days (n = 397). Main Outcome MeasuresPenicillin-nonsusceptible Streptococcus pneumoniae carriage, assessed in nasopharyngeal specimens collected at days 0, 5, 10, and 28; baseline risk factors for nonsusceptible pneumococcal carriage; and adherence to regimen, compared between the 2 groups. ResultsAt the day 28 visit, risk of penicillin-nonsusceptible pneumococcal carriage was significantly lower in the short-course, high-dose group (24%) compared with the standard-course group (32%); relative risk (RR), 0.77; 95% confidence interval (CI), 0.60-0.97;P = .03;risk of trimethoprim-sulfamethoxazole nonsusceptibility was also lower in the short-course, high-dose group (RR, 0.77; 95% CI, 0.58-1.03;P=.08).The protective effect of short-course, high-dose therapy was stronger in households with 3 or more children (RR, 0.72; 95% CI, 0.52-0.98).Adherence to treatment was higher in the short-course, high-dose group (82% vs 74%; P= .02). ConclusionShort-course, high-dose outpatient antibiotic therapy appears promising as an intervention to minimize the impact of antibiotic use on the spread of drugresistant pneumococci.
Clofibrate-Induced Antinuclear Factor and Lupus-like Syndrome
Authors: Elliott J. Howard
Journal: JAMA (1973)

<h3>To the Editor.—</h3> Clofibrate is widely used for lowering the serum cholesterol level. The case reported here suggests strongly an association between the drug<i>clofibrate</i>and the development of a systemic lupus-like reaction with antinuclear factor. There is no similar case published previously, although an unpublished case limited to dermatitis with a positive "LE" cell test result in a patient taking clofibrate was reported to the Ayerst Laboratory. Several other drugs have been implicated in the induction of a "lupuslike syndrome," commonly hydralazine, procaine, sulfonamides, and occasionally chlorpromazine, isoniazid, diphenylhydantoin, penicillin, tetracycline, quinidine, and penicillamine (references on request). This syndrome may be indistinguishable from idiopathic systemic lupus erythematosus with fever, arthritis, rash, polyserositis, hematologic abnormalities, and autoimmune reactions. <h3>Report of a Case.—</h3> A 66-year-old woman was seen from December 1972 through March 1973, with complaints of weight loss, anorexia, photophobia, malaise, arthralgias, and daily fevers to 38.3 C. Before the
After Cecilia Died
Authors: Tapendu K. Basu
Journal: Annals of Internal Medicine (1998)

Ad Libitum15 November 1998After Cecilia DiedTapendu K. Basu, MD, FRCP(C)Tapendu K. Basu, MD, FRCP(C)Bourbonnais, IL 60914Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-10-199811150-00004 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail and surely dear John would love her more.... Author, Article, and Disclosure InformationAffiliations: Bourbonnais, IL 60914Corresponding Author: Tapendu K. Basu, MD, FRCP(C), 14 Inverness Drive, Bourbonnais, IL 60914. Previousarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 November 1998Volume 129, Issue 10Page: 778 ePublished: 15 August 2000 Issue Published: 15 November 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Effect of Guar Gum on 24-hour Insulin Requirements of Insulin-dependent Diabetic Subjects as Assessed by an Artificial Pancreas
Authors: J Sandahl Christiansen, V Bonnevie-Nielsen, P Aaby Svendsen, P Rubin, B Rønn, J Nerup
Journal: Diabetes Care (1980)

The effect of guar gum on insulin requirements, mean blood glucose (MBG), and mean amplitude of glycemic excursions (MAGE) was investigated in seven insulin-dependent diabetic subjects without endogenous insulin secretion by means of an artificial pancreas (Biostator). Fifty-four hours after the withdrawal of long-acting insulin, the patients were controlled for two consecutive days by the artificial pancreas, under standardized and identical conditions, except for the ingestion of guar gum before meals on the second day. The 24-h insulin requirements were significantly reduced by 12.4% on the day with guar gum (P &amp;lt; 0.05). No statistically significant effects were observed on MBG and MAGE.
Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: A placebo-controlled clinical trial
Authors: Robert H. Squires, Anil Dhawan, Estella Alonso, Michael R. Narkewicz, Benjamin L. Shneider, Norberto Rodriguez-Baez, Dominic Dell Olio, Saul Karpen, John Bucuvalas, Steven Lobritto, Elizabeth Rand, Philip Rosenthal, Simon Horslen, Vicky Ng, Girish Subbarao, Nanda Kerkar, David Rudnick, James M. Lopez, Kathleen Schwarz, Rene Romero, Scott Elisofon, Edward Doo, Patricia R. Robuck, Sharon Lawlor, Steven H. Belle
Journal: Hepatology (2012)

N-acetylcysteine (NAC) was found to improve transplantation-free survival in only those adults with nonacetaminophen (non-APAP) acute liver failure (ALF) and grade 1-2 hepatic encephalopathy (HE). Because non-APAP ALF differs significantly between children and adults, the Pediatric Acute Liver Failure (PALF) Study Group evaluated NAC in non-APAP PALF. Children from birth through age 17 years with non-APAP ALF enrolled in the PALF registry were eligible to enter an adaptively allocated, doubly masked, placebo-controlled trial using a continuous intravenous infusion of NAC (150 mg/kg/day in 5% dextrose in water [D5W]) or placebo (D5W) for up to 7 days. The primary outcome was 1-year survival. Secondary outcomes included liver transplantation-free survival, liver transplantation (LTx), length of intensive care unit (ICU) and hospital stays, organ system failure, and maximum HE score. A total of 184 participants were enrolled in the trial with 92 in each arm. The 1-year survival did not differ significantly (P = 0.19) between the NAC (73%) and placebo (82%) treatment groups. The 1-year LTx-free survival was significantly lower (P = 0.03) in those who received NAC (35%) than those who received placebo (53%), particularly, but not significantly so, among those less than 2 years old with HE grade 0-1 (NAC 25%; placebo 60%; P = 0.0493). There were no significant differences between treatment arms for hospital or ICU length of stay, organ systems failing, or highest recorded grade of HE.
Identifying Hepatitis Type A
Authors: Samuel Vaisrub
Journal: JAMA (1975)

Diagnosis by exclusion is less than satisfying. It lacks the esthetic appeal and the epistemologic certitude of positive identification. To identify "x" as such because it is not "y" is to imply that no possibility of "z" or other alternative exists. This may not necessarily be true. Such a diagnosis is made frequently in viral hepatitis A. Originally, the excluded factor was a known parenteral route of infection. More recently it has been the hepatitis B antibody. In either case, the possibility of some other type of hepatitis (C? D?) has rarely been considered. A recently developed immune adherence antibody assay<sup>1</sup>appears to answer the need for positively identifying hepatitis A. Krugman and co-workers2 evaluated this test in 473 stored serum specimens obtained serially since 1956 from 20 patients with the clinical diagnosis of this disease. They found no detectable immune adherence antibody in any of the sera taken
REPORT OF TWO CASES OF SEVERE VOMITING OF PREGNANCY.Read in the Section of Obstetrics and Diseases of Women at the Forty-first Annual Meeting of the American Medical Association, Nashville, Tenn., May 20, 1890.
Authors: E. W. MITCHELL
Journal: JAMA (1890)

It is the purpose of this paper to present merely a clinical study of two cases without entering upon the voluminous and oft-rewritten literature of the subject. <i>Case 1</i>.—Mrs. P. S., of nervous temperament, delicate from childhood, but subject to no special organic disease, married at the age of 26, and became pregnant within a few months. Nausea and obstinate vomiting developed early. Apparently nearly all nourishment taken was rejected; she soon became so much prostrated as to be confined to her bed. Her weight in a few weeks fell from 102 to seventy pounds. Local examination revealed the signs of an early pregnancy, a conical and very long cervix, no displacement or peri-uterine tenderness. Under treatment by rest in bed, careful regulation of diet, (most of the time an exclusive milk diet), bromide of potash, and oxalate of cerium, the vomiting was somewhat mitigated and nutrition maintained. At three
Human fibroblasts maintain the viability and augment the functional response of human neutrophils in culture.
Authors: C J Ling, W F Owen, K F Austen
Journal: Journal of Clinical Investigation (1990)

When human neutrophils were co-cultured for 72 h with nontransformed human fibroblasts, 69 +/- 3% (n = 13) survived, as compared with survival levels of 2 +/- 1% (n = 15) and 26 +/- 6% (n = 7), respectively, for neutrophils cultured for the same time period in enriched medium alone or supplemented with 10 pM recombinant human granulocyte/macrophage colony-stimulating factor (rh GM-CSF). Conditioned medium from the human fibroblast cultures enhanced neutrophil survival in a dose-dependent fashion to the same level achieved with neutrophil/fibroblast co-cultures, and its soluble viability-sustaining activity was not inhibited by preincubation with neutralizing antiserum against rh GM-CSF. As compared with freshly isolated replicate samples, neutrophils co-cultured with human fibroblasts for 72 h exhibited augmented FMLP-stimulated superoxide production without spontaneous superoxide generation. This striking extension of survival and associated priming for a ligand response by neutrophils co-cultured with human fibroblasts suggests that fibroblasts may contribute to the proinflammatory properties of neutrophils in tissues.
Zomepirac Sodium
Authors: John R. Lewis
Journal: JAMA (1981)

Zomepirac sodium (Zomax) is a new orally effective nonopioid analgesic that can relieve mild to severe pain. It is more effective than aspirin or codeine alone and is as effective as analgesic combinations containing codeine or other narcotics. Given orally, zomepirac has provided analgesia comparable with usual intramuscular doses of morphine in postoperative pain. With long-term use, neither tolerance to its analgesic effect nor psychic or physical dependence has been demonstrated. Like aspirin, zomepirac has anti-inflammatory and antipyretic actions and inhibits the synthesis of prostaglandins. Zomepirac is generally well tolerated with both short-term and long-term use; gastrointestinal reactions are the most frequently occurring side effects. (<i>JAMA</i>1981;246:377-379)